Chanda Debarati, Ray Saswati, Chakraborti Debjani, Sen Sangita, Mitra Asis
Physiology, Jagannath Gupta Institute of Medical Science and Hospital, Kolkata, IND.
Physiology, Institute of Post Graduate Medical Education & Research, Kolkata, IND.
Cureus. 2022 Feb 6;14(2):e21952. doi: 10.7759/cureus.21952. eCollection 2022 Feb.
Introduction Diabetic polyneuropathy (DPN) is a common chronic complication of type 2 diabetes. The pathogenesis of DPN is still debated, but proinflammatory cytokine mediators like interleukin-6 (IL-6) are possibly involved. We conducted this cross-sectional observational study to assess whether IL-6 levels increase in patients with DPN. Materials and methods This study was conducted at the Institute of Post Graduate Medical Education and Research Hospital in Kolkata, India, from 2016 to 2017. The study included 57 patients aged 30 to 60 years diagnosed with type 2 diabetes with neuropathy on clinical examination and nerve conduction study. Patients with neuropathy due to other causes were excluded. The study participants were assigned into one of four groups. Group 1 (n=15) served as healthy control patients, Group 2 (n=12) contained patients with type 2 diabetes without neuropathy, Group 3 (n=20) contained patients with type 2 diabetes with painful neuropathy, and Group 4 (n=10) contained patients with type 2 diabetes with painless neuropathy. We compared IL-6 levels between each group. Results There was no significant difference in serum IL-6 levels between healthy controls (Group 1) and patients with type 2 diabetes without neuropathy (Group 2). However, we noted a significant increase in serum IL-6 levels among patients with painful DPN (Group 3) compared to control groups. Interestingly, serum IL-6 levels were higher in patients with painful DPN (Group 3) than patients with painless DPN (Group 4). Conclusions IL-6 increases significantly in painful diabetic neuropathy patients compared to patients with diabetes with painless neuropathy and thus may have a role in the pathogenesis of pain in DPN. Serum IL6 level can be a potential noninvasive marker of painful DPN, and it can help distinguish painful DPN from other causes of pain in patients with diabetes.
引言
糖尿病性多发性神经病（DPN）是2型糖尿病常见的慢性并发症。DPN的发病机制仍存在争议，但诸如白细胞介素-6（IL-6）等促炎细胞因子介质可能参与其中。我们开展了这项横断面观察性研究，以评估DPN患者的IL-6水平是否升高。
材料与方法
本研究于2016年至2017年在印度加尔各答的研究生医学教育与研究医院进行。该研究纳入了57例年龄在30至60岁之间的患者，这些患者经临床检查和神经传导研究确诊为2型糖尿病伴神经病。排除由其他原因导致神经病的患者。研究参与者被分为四组之一。第1组（n = 15）为健康对照患者，第2组（n = 12）为无神经病的2型糖尿病患者，第3组（n = 20）为伴有疼痛性神经病的2型糖尿病患者，第4组（n = 10）为伴有无痛性神经病的2型糖尿病患者。我们比较了各组之间的IL-6水平。
结果
健康对照组（第1组）和无神经病的2型糖尿病患者（第2组）的血清IL-6水平无显著差异。然而，我们注意到，与对照组相比，疼痛性DPN患者（第3组）的血清IL-6水平显著升高。有趣的是，疼痛性DPN患者（第3组）的血清IL-6水平高于无痛性DPN患者（第4组）。
结论
与无痛性糖尿病神经病患者相比，疼痛性糖尿病神经病患者的IL-6显著升高，因此可能在DPN疼痛的发病机制中起作用。血清IL-6水平可能是疼痛性DPN的潜在无创标志物，有助于将疼痛性DPN与糖尿病患者的其他疼痛原因区分开来。
